ClinicalTrials.gg
Active, not recruitingNCT07602465Updated Sep 10, 2026

The Impact of Blood Pressure Variability During the Induction and Surgical Periods on Postoperative Acute Kidney Injury

An observational study in Acute Kidney Injury (AKI), sponsored by Zhongda Hospital. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Zhongda Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
5,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 168 studies in Acute Kidney Injury with a site in China — 46 open to participants now, 54 under way, 1 of them phase 3. Acute Kidney Injury · China.

Planned enrollment
22nd of 105
5,000 · median 472
Started
2026
with 24 others
Observational
105 of 168
26 open now
Primary completion
2026-12
later than 21 of 53 live
Registered
154th of 168
by date

Among the 168 studies in Acute Kidney Injury with a site in China, this one is the 22nd largest by planned enrollment of the 105 observational ones that give a count, is one of 25 that started in 2026, is one of 105 observational ones, reaches primary completion later than 21 of the 53 other live ones, and was the 154th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

46 of the 168 studies in Acute Kidney Injury with a site in China are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 168 studies in Acute Kidney Injury with a site in China, or all of them as a file.
02

Study summary

The goal of this multicenter retrospective cohort study aimed to explore the effect of BPV during anesthesia induction and surgery on the occurrence of postoperative AKI in non-cardiac surgery patients.

03

Conditions studied

  • Acute Kidney Injury (AKI)

Browse trials for

Keywords

  • Acute kidney injury
  • Blood pressure variability
  • Anesthesia induction period
  • Non-cardiac surgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Southeast University Zhongda Hospital (2013-2024), Nanjing First Hospital (2016-2024), and the First Affiliated Hospital of Anhui Medical University (2013-2023)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Undergoing non-cardiac surgery;
  • Adult;

Exclusion criteria

Exclusion Criteria:

  • Undergoing urological surgeries that partially directly affect kidney function (including relief of urinary tract obstruction, nephrectomy, or kidney transplantation);
  • Surgery duration less than 60 minutes;
  • Weight \< 30 kg or > 35 kg/m2;
  • Patients who underwent reoperation within 7 days after surgery;
  • Surgeries not performed under general anesthesia;
  • ASA > IV;
  • No serum creatinine measurement available within 6 months before surgery (baseline value) or within 7 days after surgery;
  • Preexisting renal dysfunction or a diagnosis of chronic kidney disease before surgery (creatinine > 443 μmol/L);
  • No invasive blood pressure monitoring during the anesthesia induction period, or missing more than 25% of intraoperative invasive blood pressure data collection.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
5,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • HH

    High induction blood pressure variability + High surgery blood pressure variability

  • HL

    High induction blood pressure variability + Low surgery blood pressure variability

  • LH

    Low induction blood pressure variability + High surgery blood pressure variability

  • LL

    Low induction blood pressure variability + Low surgery blood pressure variability

06

What researchers measure

Primary outcomes

  1. AKI

    AKI diagnosed according to KDIGO criteria within 7 days after surgery was the primary outcome event.

    Time frame: Within 7 days after surgery.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2026
First posted
May 22, 2026
StartActual
Jun 1, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07602465
Lead sponsor
Zhongda Hospital
Collaborators
Nanjing First Hospital, Nanjing Medical University, The First Affiliated Hospital of Anhui Medical University
Responsible party
Lanyue Zhu (Attending Physician, Zhongda Hospital) — Principal investigator
First posted
May 22, 2026
Start date
Jun 1, 2026
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Sep 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion